Mutual Of America Capital Management LLC Chemo Centryx, Inc. Transaction History

Mutual Of America Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$22.17 - $51.8 $174,566 - $407,873	-7,874 Reduced 8.34%	86,576 $4.47 Million
Q2 2022 Aug 10, 2022	SELL	$15.36 - $27.51 $633,569 - $1.13 Million	-41,248 Reduced 30.4%	94,450 $2.34 Million
Q1 2022 May 02, 2022	SELL	$22.22 - $39.12 $131,142 - $230,886	-5,902 Reduced 4.17%	135,698 $3.4 Million
Q4 2021 Feb 03, 2022	BUY	$18.38 - $40.5 $408,036 - $899,100	22,200 Added 18.59%	141,600 $5.16 Million
Q3 2021 Nov 10, 2021	BUY	$13.18 - $19.83 $906,309 - $1.36 Million	68,764 Added 135.8%	119,400 $2.04 Million
Q2 2021 Aug 06, 2021	SELL	$9.59 - $50.88 $20,877 - $110,765	-2,177 Reduced 4.12%	50,636 $678,000
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $144,479 - $199,522	-2,917 Reduced 5.23%	52,813 $2.71 Million
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $480,627 - $662,807	10,172 Added 22.33%	55,730 $3.45 Million
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $361,205 - $480,750	-7,793 Reduced 14.61%	45,558 $2.5 Million
Q2 2020 Aug 06, 2020	BUY	$38.58 - $65.07 $2.06 Million - $3.47 Million	53,351 New	53,351 $3.07 Million

66.3K

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Mutual Of America Capital Management LLC with notifications on news.